Athira Pharma terminates CFO/CBO and COO/CDO; grants retention equity to CEO and VP Finance

LeonaBio, Inc.

Andrew Gengos (CFO/CBO) and Rachel Lenington (COO/CDO) terminated Oct 1, 2024; severance payments of $363,750 and $375,000 respectively.
Lenington to provide consulting through Dec 31, 2024 at $41,666.67/month; equity vests during term.
CEO Mark Litton receives 325k RSUs + 325k options (strike $0.4257); VP Finance Renninger gets 37,077 RSUs + 37,077 options (strike $0.4499).
Retention awards vest 1/3 each on Dec 31, 2024, Jun 30, 2025, and Dec 31, 2025, subject to continued service.
2024 corporate goal achievement percentage automatically increased by 25 percentage points for certain executives.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.